Researchers from McMaster University and the Firestone Institute for Respiratory Health at St. Joseph’s Healthcare Hamilton, together with colleagues at other partnering institutions, have developed a new method to treat severe asthma.
In a study of over 200 participants with severe asthma, the new treatment was shown to have improved asthma symptoms and lung function, while reducing the need for corticosteroids by up to 70%.
According to Statistics Canada, eight per cent of Canadians aged 12 or older – approximately 2.4 million people – have been diagnosed with asthma. Of that, approximately 25% are considered to be severe cases of asthma.
Current treatments for severe asthma often include high doses of corticosteroids, such as prednisone, to control exacerbations. Reducing the need for corticosteroids with alternative treatments is preferable, since these medications are associated with serious side effects from prolonged use – including multi-organ toxicities and immunosuppression.
Parameswaran Nair, professor of medicine at McMaster and staff respirologist at St. Joseph’s Healthcare Hamilton, along with a team of researchers found that an antibody called dupilumab is effective in treating severe asthma in place of high doses of prednisone.
The results were published in the New England Journal of Medicine, one of the world’s most influential medical publications.
Researchers sought participants who had been using oral corticosteroids (prednisone) to treat severe asthma for at least six months prior to the study. In addition to their standard regimen of corticosteroids, patients received either dupilumab or a placebo during the 24 week trial. The corticosteroid dose was gradually reduced during weeks four to 20, and maintained at a low level for the final four weeks.
“The ability of dupilumab to increase lung function as markedly as it did in this study, even in the face of [corticosteroid] withdrawal, indicates that it appears to be inhibiting key drivers of lung inflammation,” the researchers noted.
Dupilumab works to treat asthma by blocking two specific proteins (called interleukin-4 and interleukin-13) that are associated with inflammation of the airways.
This technique was based on Nair’s previous research, (published in the New England Journal of Medicine in 2009 and in 2017). Those studies found that blocking another protein, interleukin-5, allowed patients with high eosinophil levels in their blood and airways to reduce their corticosteroid dose. Eosinophils are a type of white blood cell involved with the production of interleukins. High eosinophil levels are directly linked to an increased risk of severe asthma.
Unlike the previous studies, dupilumab was shown to be effective regardless of patients’ eosinophil levels. Despite the reduced prednisone dose, patients in this study not only experienced a decrease in asthma exacerbations, but their lung function also improved significantly.
“Ultimately, our goal is to find new treatment pathways that allow us to circumvent the use of corticosteroids,” said Nair.
“Since dupilumab showed a significant improvement on asthma control regardless of eosinophil levels, we may be able to use this treatment for a wider range of patients than we previously thought possible. This might be due to the broad effects on inflammation in asthma of the two proteins that we were able to block with dupilumab. The treatment was not associated with any serious side effects.”
The Latest on: Asthma
via Google News
The Latest on: Asthma
- Monoclonal antibody decreases asthma attacks by 27% in children and adolescents of coloron August 10, 2022 at 5:42 pm
A monoclonal antibody, mepolizumab, decreased asthma attacks by 27% in Black and Hispanic children and adolescents who have a form of severe asthma, are prone to asthma attacks and live in low-income ...
- Monoclonal antibody reduces asthma attacks in urban youthon August 10, 2022 at 3:30 pm
A National Institutes of Health clinical trial has found that a monoclonal antibody, mepolizumab, decreased asthma attacks by 27% in Black and Hispanic children and adolescents who have a form of ...
- National study involving Madison doctor asks if antibiotics can help treat asthmaon August 10, 2022 at 11:35 am
Some asthma might involve infections of the bacterium Chlamydia pneumoniae, says Dr. David Hahn, who wrote the book, “A Cure for Asthma? What Your Doctor Isn’t Telling You — and ...
- Potential long-term treatment for asthma foundon August 10, 2022 at 10:04 am
A possible way to tackle one of the underlying causes of asthma has been developed. In tests in mice, the researchers were able to virtually eliminate asthmatic symptoms within two weeks and return ...
- New treatment for a root cause of asthma proves promising in mice testson August 9, 2022 at 8:08 pm
Asthma is an incredibly common disease that’s usually managed by treating the symptoms. But new research shows a potential way to target a root cause of the disease, with a molecule preventing ...
- Asthma in the spotlight as Upstream Bio starts trial and UK universities propose new long-term treatmenton August 9, 2022 at 11:42 am
Upstream Bio has initiated a phase 1b study of UPB-101 in asthma patients with the dosing of the first patient.
- Former asthma sufferer Biden has cough, but not COVID, White House sayson August 9, 2022 at 11:41 am
U.S. President Joe Biden continues to test negative for COVID-19 but is suffering its lingering effects, the White House press office said on Tuesday, after he coughed repeatedly through a speech on ...
- Researchers develop a potential way to tackle one of the underlying causes of asthmaon August 9, 2022 at 9:53 am
A possible way to tackle one of the underlying causes of asthma has been developed by researchers from Aston University and Imperial College London.
- Asthma-Related Emergency Department Visits Can Indicate Poor Housing Conditionson August 8, 2022 at 10:28 am
Emergency department (ED) asthma visits can be an indicator of poor housing conditions, according to results of a study done in New Haven, Connecticut.
via Bing News